http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 17:38:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Jul+07++Filed+by%3A+Horn+Kinney/26754035.html si-local-file:///var/storage/secattach/20260709/26754035.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Jul+07++Filed+by%3A+Horn+Kinney/26754035.html Thu, 09 Jul 2026 17:38:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Jul+07++Filed+by%3A+Horn+Kinney/26754035.html si-local-file:///var/storage/secattach/20260709/26754035.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Jul+07++Filed+by%3A+Horn+Kinney/26754035.html Thu, 09 Jul 2026 17:38:00 -0400 IMNM O.48629524 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Immunome+Inc.+%28IMNM%29/26749830.html <p>H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $40.00 price target on Immunome Inc. (NASDAQ: IMNM).</p><p>The analyst commented: "The FDA has accepted Immunome’s NDA for varegacestat with a PDAFU date of April 28th, 2027. The filing is supported by the Phase 3 RINGSIDE trial data which met its primary PFS endpoint with an 84% reduction in risk of progression (HR 0.16, p<0.0001) and showed a 56% ORR vs. 9% placebo (p<0.0001) alongside a faster median time to response and reduction in tumor volume (83% at week 24 vs. +11% in placebo). The PFS benefit held consistently across http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Immunome+Inc.+%28IMNM%29/26749830.html Thu, 09 Jul 2026 06:48:43 -0400 IMNM http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html <p>Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.</p> <p>The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p&lt;0.0001). The objective response http://www.streetinsider.com/FDA/FDA+accepts+Immunome+drug+application+for+desmoid+tumor+treatment/26744253.html Wed, 08 Jul 2026 07:30:14 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Press+Releases/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html <ul class="bwlistdisc"> <li> PDUFA target action date set for April 28, 2027 </li> <li> Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved </li> </ul> <p> BOTHELL, Wash.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54566700&amp;newsitemid=20260708283482&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=d334227e04f8c2b86fb94278614d4d02" shape="rect">Immunome, Inc.</a> (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date http://www.streetinsider.com/Business+Wire/Immunome+Announces+U.S.+FDA+Acceptance+of+New+Drug+Application+for+Varegacestat+for+the+Treatment+of+Adults+with+Desmoid+Tumors/26744242.html Wed, 08 Jul 2026 07:30:00 -0400 A.06822034 A.31066700 A.50216726 IMNM O.20026344 O.21612337 O.22422661 O.48629524